BIIB
Price
$132.87
Change
-$0.32 (-0.24%)
Updated
Jul 3 closing price
Capitalization
31.34B
19 days until earnings call
SNY
Price
$48.30
Change
-$1.01 (-2.05%)
Updated
Jul 3 closing price
Capitalization
122.61B
27 days until earnings call
Interact to see
Advertisement

BIIB vs SNY

Header iconBIIB vs SNY Comparison
Open Charts BIIB vs SNYBanner chart's image
Biogen
Price$132.87
Change-$0.32 (-0.24%)
Volume$633.33K
Capitalization31.34B
Sanofi ADS
Price$48.30
Change-$1.01 (-2.05%)
Volume$1.56M
Capitalization122.61B
BIIB vs SNY Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. SNY commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and SNY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (BIIB: $132.87 vs. SNY: $48.30)
Brand notoriety: BIIB: Notable vs. SNY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 41% vs. SNY: 72%
Market capitalization -- BIIB: $31.34B vs. SNY: $122.61B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. SNY’s [@Pharmaceuticals: Major] market capitalization is $122.61B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, SNY is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while SNY’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 2 bearish.
  • SNY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than SNY.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +4.69% price change this week, while SNY (@Pharmaceuticals: Major) price change was -0.14% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.13%. For the same industry, the average monthly price growth was +2.56%, and the average quarterly price growth was +9.33%.

Reported Earning Dates

BIIB is expected to report earnings on Jul 23, 2025.

SNY is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.13% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNY($123B) has a higher market cap than BIIB($31.3B). BIIB has higher P/E ratio than SNY: BIIB (26.95) vs SNY (20.80). SNY YTD gains are higher at: 4.583 vs. BIIB (-13.111). SNY has higher annual earnings (EBITDA): 12.6B vs. BIIB (2.04B). SNY has more cash in the bank: 8.98B vs. BIIB (1.05B). BIIB has less debt than SNY: BIIB (7.34B) vs SNY (18.4B). SNY has higher revenues than BIIB: SNY (46.4B) vs BIIB (9.84B).
BIIBSNYBIIB / SNY
Capitalization31.3B123B25%
EBITDA2.04B12.6B16%
Gain YTD-13.1114.583-286%
P/E Ratio26.9520.80130%
Revenue9.84B46.4B21%
Total Cash1.05B8.98B12%
Total Debt7.34B18.4B40%
FUNDAMENTALS RATINGS
BIIB vs SNY: Fundamental Ratings
BIIB
SNY
OUTLOOK RATING
1..100
6915
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
7
Undervalued
PROFIT vs RISK RATING
1..100
10068
SMR RATING
1..100
7175
PRICE GROWTH RATING
1..100
6258
P/E GROWTH RATING
1..100
9691
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNY's Valuation (7) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (88) in the Biotechnology industry. This means that SNY’s stock grew significantly faster than BIIB’s over the last 12 months.

SNY's Profit vs Risk Rating (68) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that SNY’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's SMR Rating (71) in the Biotechnology industry is in the same range as SNY (75) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to SNY’s over the last 12 months.

SNY's Price Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as BIIB (62) in the Biotechnology industry. This means that SNY’s stock grew similarly to BIIB’s over the last 12 months.

SNY's P/E Growth Rating (91) in the Pharmaceuticals Major industry is in the same range as BIIB (96) in the Biotechnology industry. This means that SNY’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBSNY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 2 days ago
39%
Momentum
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
53%
MACD
ODDS (%)
Bullish Trend 2 days ago
47%
Bullish Trend 2 days ago
51%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
42%
Advances
ODDS (%)
Bullish Trend 3 days ago
54%
Bullish Trend 3 days ago
51%
Declines
ODDS (%)
Bearish Trend 5 days ago
70%
Bearish Trend 17 days ago
49%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
50%
Bullish Trend 2 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
33%
Bearish Trend 2 days ago
45%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CIBR75.931.41
+1.89%
First Trust NASDAQ Cybersecurity ETF
XUSP42.770.53
+1.25%
Innovator Uncapped Accelerated US Eq ETF
DBEU44.340.09
+0.20%
Xtrackers MSCI Europe Hedged Equity ETF
XIJN30.860.05
+0.17%
FT Vest U.S. Eq Bffr & Prm Inc ETF -June
TAXX50.58N/A
-0.01%
BondBloxx IR+M Tax-Awr Shrt Dur ETF

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-0.24%
AMGN - BIIB
55%
Loosely correlated
+0.47%
PFE - BIIB
49%
Loosely correlated
+0.24%
SNY - BIIB
47%
Loosely correlated
-2.05%
NVS - BIIB
45%
Loosely correlated
-1.54%
GSK - BIIB
44%
Loosely correlated
-0.86%
More

SNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNY has been loosely correlated with SNYNF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then SNYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNY
1D Price
Change %
SNY100%
-2.05%
SNYNF - SNY
61%
Loosely correlated
+1.74%
GSK - SNY
52%
Loosely correlated
-0.86%
NVS - SNY
48%
Loosely correlated
-1.54%
PFE - SNY
46%
Loosely correlated
+0.24%
AZN - SNY
45%
Loosely correlated
-2.36%
More